Evidence map›Paper›PMID 35934087›Full record

ReviewNeuroscience and biobehavioral reviews2022

The gut microbiome and Alzheimer's disease: Complex and bidirectional interactions.

Rawan Tarawneh, Elena Penhos

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Rawan TarawnehDepartment of Neurology, Center for Memory and Aging, Alzheimer Disease Research Center, The University of New Mexico, Albuquerque, NM 87106, USA. Electronic address: raltarawneh@salud.unm.edu.
Elena PenhosCollege of Medicine, The Ohio State University, Columbus, OH, USA 43210.
The Ohio State University · USUniversity of New Mexico · US

Funding

Scientific CoreP20AG068077 · NIA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2020 to 2022
$3.1M
Alzheimer’s Disease Biomarker for Diagnosis and PrognosisR21AG067755 · NIA · OHIO STATE UNIVERSITY · PI AMER, AMAL O, TARAWNEH, RAWAN · 2020 to 2021
$417k
NIA NIH HHS P20 AG068077NIA NIH HHS R21 AG067755
6 · The paper itself

Abstract

Structural and functional alterations to the gut microbiome, referred to as gut dysbiosis, have emerged as potential key mediators of neurodegeneration and Alzheimer disease (AD) pathogenesis through the "gut -brain" axis. Emerging data from animal and clinical studies support an important role for gut dysbiosis in mediating neuroinflammation, central and peripheral immune dysregulation, abnormal brain protein aggregation, and impaired intestinal and brain barrier permeability, leading to neuronal loss and cognitive impairment. Gut dysbiosis has also been shown to directly influence various mechanisms involved in neuronal growth and repair, synaptic plasticity, and memory and learning functions. Aging and lifestyle factors including diet, exercise, sleep, and stress influence AD risk through gut dysbiosis. Furthermore, AD is associated with characteristic gut microbial signatures which offer value as potential markers of disease severity and progression. Together, these findings suggest the presence of a complex bidirectional relationship between AD and the gut microbiome and highlight the utility of gut modulation strategies as potential preventative or therapeutic strategies in AD. We here review the current literature regarding the role of the gut-brain axis in AD pathogenesis and its potential role as a future therapeutic target in AD treatment and/or prevention.

Indexed as

Alzheimer DiseaseCognitive DysfunctionGastrointestinal MicrobiomeAnimalsBrainDysbiosisProtein AggregatesProtein AggregatesAgeAlzheimer diseaseGut microbiomeLifestylePrevention

Identifiers

PMID35934087
PMCPMC9637435
OpenAlexW4289779082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.